1-855-378-42281-855-378-4228
One of the out-patient rehab options for clients in Fresno struggling with opioid dependence and addiction is opioid maintenance therapy. Some clinics and doctors are certified to give certain meds to opioid addicted people, many of which are opioid-based themselves and are habit forming. With low enough doses the client doesn't experience being high and also does not have acute cravings and isn't in opioid withdrawal. Methadone is the first drug tried for this reason, but there are other options to pick from.
Methadone is an opioid and is meant to be taken at an outpatient medical center certified to dispense the drug, that is taken daily in liquid or pill form. The price of the drug is around under $200 per month. Buprenorphine is also an opioid-based med, and is in pill form often taken every other day. But unlike Methadone that is only be administered in highly well-regulated medical centers, Buprenorphine can be prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is approximately $300 monthly for the generic of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, that is a med that reverses the effects of opioids. Someone taking this version of the drug, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken daily, and costs about $450 monthly. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other drugs mentioned it's an opioid blocker and is not an opiate. There is an option to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents someone from feeling high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 monthly.
There are 4 Drug and Alcohol Treatment Programs offering this service near Fresno, TX
For Additional Alcohol and Drug Treatment Programs Near Fresno, Click Here.
